The launch of PatroLab is a pivotal milestone, marking a paradigm shift in biologics development and manufacturing
The applications aim to launch Phase Ib/II trials for relapsed/refractory multiple myeloma and primary plasma cell leukemia, respectively
The study is being conducted under a USFDA IND, has received U.S. Fast Track Designation for SLE-ITP, and has obtained IND approval from China’s Center for Drug Evaluation
The expanded mbDNA portfolio delivers enhanced stability, reduced immunogenicity, and broad compatibility with gene insertion and expression technologies
This is the first industry-academia collaboration in the country, initiated through the CSR route, for advancing research in the areas of immuno-therapeutics and regenerative medicines
CSIR-IGIB advances indigenous CRISPR Trials on sickle cell anaemia, anti-microbial resistance, liver fibrosis and rare disorders
This is specifically for the evaluation of medicines that, if approved, would provide a significant improvement in the safety or effectiveness of the treatment, prevention, or diagnosis of a serious condition
Sumitomo Chemical began its nucleic acid drug substance contract manufacturing business in 2013
This facility represents a significant step in Croda’s Pharma business strategy to ‘Empower biologics delivery’
Cellectis is also eligible to receive an investigational new drug (IND) option fee and development
Subscribe To Our Newsletter & Stay Updated
